While protein chips will be a new area for CombiMatrix’s array business (see story in this issue, "Jumping Off Fence, CombiMatrix Decides to Enter Developing Protein Array Marketplace"), its DNA CustomArray sales appear to be taking off. The company’s revenues for the fourth quarter of 2004 were $522,000, up from $53,000 during the same quarter a year ago. Revenues comprised $390,000 from government contracts — $73,000 of which were array sales — and $132,000 from CustomArray products and services.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.